Evidence map›Paper›PMID 30076379›Full record

ArticleScientific reports2018

Heterotetrameric annexin A2/S100A10 (A2t) is essential for oncogenic human papillomavirus trafficking and capsid disassembly, and protects virions from lysosomal degradation.

Julia R Taylor, Daniel J Fernandez, Shantaé M Thornton, Joseph G Skeate, Kim P Lühen, Diane M Da Silva, Ralf Langen, W Martin Kast

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. bioRxiv : the preprint server for biology · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Annexin A2: A Double-Edged Sword in Pathogen Infection.Pathogens (Basel, Switzerland) · 2024
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Julia R TaylorDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA, USA.
Daniel J FernandezDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA, USA.
Shantaé M ThorntonDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA, USA.
Joseph G SkeateDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA, USA.
Kim P LühenNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Diane M Da SilvaDepartment of Obstetrics & Gynecology, University of Southern California, Los Angeles, CA, USA.
Ralf LangenDepartment of Biochemistry and Molecular Biology, University of Southern California, Los Angeles, CA, USA.
W Martin KastDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA, USA. Martin.Kast@med.usc.edu.
University of Southern California · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI William Dean Wallace · 1985 to 2026
$181.4M
Southern California Clinical and Translational Science InstituteUL1TR001855 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Thomas A Buchanan, Michele D. Kipke · 2016 to 2026
$81.3M
VLP VACCINES AGAINST HPV INDUCED TUMORSR01CA074397 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KAST, WIJBE MARTIN · 1997 to 2020
$5.5M
Contributions of the Annexin A2 Heterotetramer to HPV16 EndocytosisF31AI136312 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TAYLOR, JULIA ROSE · 2018 to 2018
$28k
NCATS NIH HHS UL1 TR001855NCI NIH HHS P30 CA014089NCI NIH HHS R01 CA074397NIAID NIH HHS F31 AI136312
6 · The paper itself

Abstract

Human papillomavirus (HPV) entry into epithelial cells is independent of canonical endocytic pathways. Upon interaction with host cells, HPV establishes infection by traversing through an endocytic pathway that is clathrin- and caveolin-independent, but dependent on the annexin A2/S100A10 heterotetramer (A2t). We examined the contribution of monomeric annexin A2 (AnxA2) vs. A2t in HPV infection and endocytosis, and further characterized the role of these molecules in protein trafficking. We specifically show that cell surface A2t is not required for HPV attachment, and in the absence of A2t virion internalization remains clathrin-independent. Without A2t, viral progression from early endosomes to multivesicular endosomes is significantly inhibited, capsid uncoating is dramatically reduced, and lysosomal degradation of HPV is accelerated. Furthermore, we present evidence that AnxA2 forms a complex with CD63, a known mediator of HPV trafficking. Overall, the observed reduction in infection is less significant in the absence of S100A10 alone compared to full A2t, supporting an independent role for monomeric AnxA2. More broadly, we show that successful infection by multiple oncogenic HPV types is dependent on A2t. These findings suggest that A2t is a central mediator of high-risk HPV intracellular trafficking post-entry and pre-viral uncoating.

Indexed as

Annexin A2Capsid ProteinsEndocytosisEpithelial CellsHeLa CellsHuman papillomavirus 16HumansLysosomesPapillomaviridaePapillomavirus InfectionsProtein MultimerizationProtein TransportProteolysisS100 Calcium Binding Protein A10S100 ProteinsVirionAnnexin A2Capsid ProteinsS100 Calcium Binding Protein A10S100 Proteins

Identifiers

PMID30076379
PMCPMC6076308
OpenAlexW2887612441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.